Great Elm Capital Corp. (GECC)
NASDAQ: GECC · Real-Time Price · USD
10.98
-0.02 (-0.14%)
At close: Aug 1, 2025, 4:00 PM
10.98
+0.01 (0.05%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Intra-Cellular Therapies.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Intra-Cellular Therapies.
Recommendation Trends
| Rating | Apr '22 | May '22 | Jun '22 | Jul '22 |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Janney Montgomery Scott | Janney Montgomery Scott | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jul 12, 2022 |
| Oppenheimer | Oppenheimer | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Apr 8, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $84 | Buy | Initiates | $84 | +665.38% | Jun 28, 2017 |
Financial Forecast
Revenue This Year
51.94M
from 39.32M
Increased by 32.09%
Revenue Next Year
52.20M
from 51.94M
Increased by 0.51%
EPS This Year
1.65
from 0.36
Increased by 357.82%
EPS Next Year
1.62
from 1.65
Decreased by -2.16%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 54.7M | 56.2M |
| Avg | 51.9M | 52.2M |
| Low | 49.3M | 47.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 39.1% | 8.2% |
| Avg | 32.1% | 0.5% |
| Low | 25.5% | -8.5% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 1.85 | 1.82 |
| Avg | 1.65 | 1.62 |
| Low | 1.48 | 1.42 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | 412.0% | 9.9% |
| Avg | 357.8% | -2.2% |
| Low | 310.0% | -14.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.